drugset / Trial / NCT00511706

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

NCT00511706

Phase 2 Completed 243 enrolled Allergan
RandomizedSingle-groupTriple-blindTreatment

Summary

The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Timeline

Start
2007-11-01
Primary completion
2009-03-01
Completion
2009-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 700 ug Intravitreal
Background Ranibizumab Monoclonal antibody 500 ug